Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
NCT07077486Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2025
- Primary completion
- Oct 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of telitacicept in systemic lupus erythematosus (SLE), interstitial lung disease (ILD), sponsored by Tongji Hospital. Started Aug 2025; status: recruiting.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT07077486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077486.